Understanding how the immune system controls hepatitis B in people with HIV.
Official title: HBV-specific T cell immunity in HBV/HIV coinfection
Funded at University of Alabama at Birmingham · NIH-10900779 · Data updated 2026-11-12
This study is looking at how the immune system responds to hepatitis B in people who also have HIV, with the goal of finding better treatments to help them manage both infections and improve their health.
Quick facts
| Grant type | R37 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Alabama at Birmingham NIH-funded |
| Lab location | 1 site (Birmingham, United States) |
| Project start | August 7, 2023 |
| Project end | July 31, 2028 |
| Funding year | 2024 |
| Award (this year) | $725,950 |
| NIH project number | 5R37AI179640-02 |
| Project ID | NIH-10900779 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals over 21 years old who are living with both HIV and hepatitis B virus.
✕Less likely to help
Patients who do not have HIV or hepatitis B virus may not benefit from this research.
What this research studies
This research investigates the immune response to hepatitis B virus (HBV) in individuals who are also living with HIV. It aims to understand the biology of HBV and the role of specific immune cells, particularly CD4 T cells, in controlling HBV infection. The study will explore novel antiviral and immunotherapy approaches to improve treatment outcomes for those with HBV/HIV coinfection. By focusing on the mechanisms that lead to a functional cure of HBV, the research seeks to enhance current therapies and address the high mortality rates associated with this coinfection.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment options and potentially a cure for hepatitis B in patients who are also living with HIV.
How similar studies have gone: While there has been limited research specifically on HBV/HIV coinfection, studies on HBV therapies have shown promise, indicating potential for success in this area.
Where this research is happening
-
University of Alabama at Birmingham
Birmingham, United States Active
Researchers
- Principal investigator: Vinikoor, Michael Jeffrey — University of Alabama at Birmingham
- Study coordinator: Vinikoor, Michael Jeffrey
Related research
Other NIH-funded projects on the same topics.
-
IOP and CSF Pressure in Glaucoma Risk
This grant studies how eye pressure and cerebrospinal fluid pressure together influence glaucoma risk and vision loss.
-
Exploring how Down syndrome affects optic nerve health in kids
A study using a mouse model to understand why optic nerve problems are common in children with Down syndrome and how to prevent them.
-
Global bromocriptine trial for postpartum cardiomyopathy
A large international study will test whether adding bromocriptine to standard heart failure treatment helps new mothers with peripartum cardiomyopathy.
-
Global Bromocriptine Add-on for Postpartum Heart Failure (GLOBal PPCM)
A large international study will test whether adding the dopamine agonist bromocriptine to standard heart failure care helps postpartum women with a specific heart condition.
-
Global Bromocriptine Trial for Postpartum Heart Failure (GLOBal PPCM)
A large international study will test whether adding bromocriptine to standard heart-failure care helps women with postpartum cardiomyopathy.
-
Bromocriptine as add-on therapy for postpartum cardiomyopathy across multiple sites
A large international study will test whether adding bromocriptine to standard heart failure treatment helps new mothers with postpartum cardiomyopathy.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.